| Ytd | -46.32% | |
| 1y | -62.56% |
| Open | 0.62 | Prev Close | 0.61 | Low | 0.60 | High | 0.63 | Mkt Cap | 5.54M |
| Vol | 80.51K | Avg Vol | 2.33M | EPS | -1.24 | P/E | -0.49 | Forward P/E | -0.47 |
| Beta | 1.51 | Short Ratio | 0.62 | Inst. Own | 21.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.15 | 200-d Avg | 1.75 | 1yr Est | 6.00 |
TRAW News
Traws Pharma, Inc. $139,185,641.25 Common StockPreferred StockDebt SecuritiesWarrantsUnits This pros
The updated data package is expected to be resubmitted to MHRA during the third quarter of 2026. 
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenz
Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory c
Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining i
Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply ag
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a cl
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based war
Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “T
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylacti
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shot up 8.8% on Monday. The stock traded as high
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for th
SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery so
DOVER, Del. , Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc., a leading life sciences accelerator
Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease re
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidenc
Traws Pharma, Inc. (NASDAQ:TRAW ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Compan
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illne